# Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

Source: https://onco.cc/trials/nct04315324/  
OnCo record `nct04315324` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AST-3424 run by SWOG Cancer Research Network, active and no longer recruiting.

## Summary

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) is a phase 1/2 interventional study registered as NCT04315324 by SWOG Cancer Research Network, with 67 participants planned, started 2021-02-08. Conditions recorded: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma and T Lymphoblastic Lymphoma. Interventions recorded: AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Computed Tomography.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04315324
- Phase: 1/2
- Setting: A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
- Sponsor: SWOG Cancer Research Network
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT04315324: https://clinicaltrials.gov/study/NCT04315324

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [AST-3424](https://onco.cc/drugs/ast-3424/)
- companies: [Ascentawits Pharmaceuticals](https://onco.cc/companies/ascentawits-pharmaceuticals/), [OBI Pharma](https://onco.cc/companies/obi-pharma/), [Zhejiang Hisun Pharmaceutical](https://onco.cc/companies/zhejiang-hisun/)

---
JSON: https://onco.cc/api/v1/entities/nct04315324.json